文献速递姑息放疗与转移瘤

放疗能否恢复对检查点抑制剂耐药的转移性黑色素瘤的免疫治疗反应:挽救免疫治疗耐药疾病的机构经验

Can radiation restore immunotherapy response in metastatic melanoma refractory to checkpoint inhibitors: An institutional experience in salvaging immunotherapy resistant disease.
PubMed 文献 · Radiother Oncol · 2023-05-11

本研究评估转移性黑色素瘤患者在免疫治疗(IO)期间进展后,对进展部位行放疗(RT)同步IO的总体治疗反应与安全性。原文摘要未报告具体样本量、疗效数值或安全性结果。

要点

  • 研究对象为IO期间进展的转移性黑色素瘤患者。
  • 干预为对进展部位行RT同步IO。
  • 目的是评估总体治疗反应和安全性。

核心结论

  • 原文摘要未报告研究结论。

研究设计与样本

  • 机构经验性研究,评估IO期间进展的转移性黑色素瘤患者对进展部位行RT同步IO的总体治疗反应与安全性。

主要发现

  • 原文摘要未报告具体疗效或安全性数值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Melanoma is an immunogenically active tumor with abundantly expressed lymphoid infiltration. Immunotherapy(IO) has proven as a promising treatment option for melanoma but treatment resistance remains as an issue in the majority of patients.There is emerging evidence that radiotherapy (RT) could modulate the tumor microenvironment, increase antigen presentation, and augment adaptive antitumor immunity. Our objective is to evaluate overall treatment response and safety in patients with metastatic melanoma who progressed while on IO, and were treated with RT concurrently with IO for progressive sites.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Alhumaid M, Dinakaran D, Smylie M, et al. Can radiation restore immunotherapy response in metastatic melanoma refractory to checkpoint inhibitors: An institutional experience in salvaging immunotherapy resistant disease. Radiother Oncol. 2023. PMID: 37178931. doi:10.1016/j.radonc.2023.109712

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。